New Approval for Drug Treating Large B-Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36136022/
The Food and Drug Administration has approved lisocabtagene maraleucel (Breyanzi) to treat large B-cell lymphoma in adults who relapsed or were refractory after first-line treatment.Lisocabtagene maraleucel continues to be prescribed...
Conclusions: The Food and Drug Administration has approved lisocabtagene maraleucel (Breyanzi) to treat large B-cell lymphoma in adults who relapsed or were refractory after first-line treatment.
"
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36149968/
Lisocabtagene maraleucel (liso-cel) has shown promising efficacy in clinical trials for patients with relapsed/refractory large B-cell lymphoma (LBCL). We present health-related quality of life (HRQOL) results from the TRANSFORM study,...
Conclusions: Most HRQOL domains at baseline among the study population were generally comparable to the general population. The results of this analysis demonstrate that treatment with liso-cel improved some HRQOL domains, including global health status/QOL, cognitive functioning, and fatigue, and maintained HRQOL in most of the remaining...
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36505886/
For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach...
Conclusions: Conclusions/Relevance: Here, we discuss recent randomized phase 3 clinical trials using axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in the second-line therapy setting compared with the standard of care in transplant-eligible patients who have DLBCL R/R within 12 months of completing chemo-immunotherapy,...
Large B-cell lymphoma with IRF4 gene rearrangements: differences in clinicopathologic, immunophenotypic and cytogenetic features between pediatric and adult patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36470475/
Large B-cell lymphoma (LBL) with interferon regulatory factor 4 (IRF4) rearrangement (LBL-IRF4), a provisional entity in the 2017 WHO classification, primarily arises in children and young adults and has a...
Conclusions: From a database of all internal and external cases (08/01/2015 to 12/01/2020) on which interphase fluorescence in situ hybridization was performed at the Mayo Clinic, we identified 43 patients with B-cell lymphoma and IRF4 rearrangements. Consistent features included large cell morphology, expression of CD20, BCL6, and MUM1, and...
Role of Artificial Intelligence and Machine Learning in Prediction, Diagnosis, and Prognosis of Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36475188/
Cancer is one of the most devastating, fatal, dangerous, and unpredictable ailments. To reduce the risk of fatality in this disease, we need some ways to predict the disease, diagnose...
Conclusions: Both solid and non-solid tumors can be diagnosed precisely with the help of AI and ML algorithms. The prognosis of the disease can also be forecasted with AI and its approaches like deep learning. This improvement in cancer care is a turning point in advanced healthcare and will deeply impact patient’s life for good.